INSM
Price
$71.26
Change
+$0.66 (+0.93%)
Updated
Nov 14 closing price
97 days until earnings call
RARE
Price
$47.64
Change
-$1.07 (-2.20%)
Updated
Nov 14 closing price
90 days until earnings call
Ad is loading...

INSM vs RARE

Header iconINSM vs RARE Comparison
Open Charts INSM vs RAREBanner chart's image
Insmed
Price$71.26
Change+$0.66 (+0.93%)
Volume$2.02M
CapitalizationN/A
Ultragenyx Pharmaceutical
Price$47.64
Change-$1.07 (-2.20%)
Volume$586.33K
CapitalizationN/A
INSM vs RARE Comparison Chart
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
INSM vs. RARE commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a StrongBuy and RARE is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (INSM: $71.26 vs. RARE: $47.64)
Brand notoriety: INSM and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 136% vs. RARE: 80%
Market capitalization -- INSM: $12.75B vs. RARE: $4.4B
INSM [@Biotechnology] is valued at $12.75B. RARE’s [@Biotechnology] market capitalization is $4.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, INSM is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 3 bullish TA indicator(s).

  • INSM’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INSM is a better buy in the short-term than RARE.

Price Growth

INSM (@Biotechnology) experienced а -0.60% price change this week, while RARE (@Biotechnology) price change was -5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.07%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +5.23%.

Reported Earning Dates

INSM is expected to report earnings on Feb 20, 2025.

RARE is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Biotechnology (-2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($12.7B) has a higher market cap than RARE($4.4B). INSM YTD gains are higher at: 129.945 vs. RARE (-0.376).
INSMRAREINSM / RARE
Capitalization12.7B4.4B289%
EBITDA-769.56MN/A-
Gain YTD129.945-0.376-34,522%
P/E RatioN/AN/A-
Revenue343MN/A-
Total Cash1.47BN/A-
Total Debt1BN/A-
FUNDAMENTALS RATINGS
INSM vs RARE: Fundamental Ratings
INSM
RARE
OUTLOOK RATING
1..100
6861
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
1593
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3657
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (71) in the Biotechnology industry is in the same range as INSM (82). This means that RARE’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (15) in the Biotechnology industry is significantly better than the same rating for RARE (93). This means that INSM’s stock grew significantly faster than RARE’s over the last 12 months.

RARE's SMR Rating (99) in the Biotechnology industry is in the same range as INSM (100). This means that RARE’s stock grew similarly to INSM’s over the last 12 months.

INSM's Price Growth Rating (36) in the Biotechnology industry is in the same range as RARE (57). This means that INSM’s stock grew similarly to RARE’s over the last 12 months.

INSM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that INSM’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMRARE
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
72%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 8 days ago
0%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
INSM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with NOXOF. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then NOXOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+0.93%
NOXOF - INSM
88%
Closely correlated
N/A
THAR - INSM
76%
Closely correlated
+2.29%
NWPHF - INSM
49%
Loosely correlated
N/A
AGIO - INSM
44%
Loosely correlated
-5.46%
RARE - INSM
38%
Loosely correlated
-2.20%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with DNLI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-2.20%
DNLI - RARE
43%
Loosely correlated
-3.98%
CRNX - RARE
42%
Loosely correlated
+1.26%
ROIV - RARE
40%
Loosely correlated
-2.59%
PGEN - RARE
40%
Loosely correlated
-3.58%
FOLD - RARE
40%
Loosely correlated
-2.70%
More